Effect size | Standardized response mean | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
OPAL Broaden | OPAL Beyond | OPAL Broaden | OPAL Beyond | |||||||
Tofacitinib 5 mg BID N = 68 | Tofacitinib 10 mg BID N = 62 | Adalimumab 40 mg SC Q2W N = 66 | Tofacitinib 5 mg BID N = 64 | Tofacitinib 10 mg BID N = 62 | Tofacitinib 5 mg BID N = 68 | Tofacitinib 10 mg BID N = 62 | Adalimumab 40 mg SC Q2W N = 66 | Tofacitinib 5 mg BID N = 64 | Tofacitinib 10 mg BID N = 62 | |
Month 3 | ||||||||||
PASDAS | 1.73 | 2.40 | 1.69 | 1.53 | 1.84 | 1.42 | 1.75 | 1.73 | 1.26 | 1.53 |
DAPSA | 0.90 | 1.23 | 1.05 | 0.81 | 0.84 | 1.05 | 1.25 | 1.47 | 0.94 | 1.15 |
CPDAI | 1.03 | 1.53 | 1.05 | 1.41 | 1.45 | 0.89 | 1.27 | 1.11 | 1.11 | 1.49 |
DAS28–3(CRP) | 1.47 | 1.77 | 1.37 | 1.07 | 1.16 | 1.25 | 1.46 | 1.50 | 1.14 | 1.29 |
Month 6 | ||||||||||
PASDAS | 2.17 | 2.81 | 1.98 | 1.88 | 2.10 | 1.76 | 2.11 | 1.64 | 1.49 | 1.74 |
DAPSA | 1.15 | 1.43 | 1.24 | 0.97 | 0.92 | 1.18 | 1.34 | 1.43 | 1.11 | 0.94 |
CPDAI | 1.53 | 1.88 | 1.44 | 1.65 | 1.75 | 1.52 | 1.52 | 1.25 | 1.23 | 1.55 |
DAS28–3(CRP) | 1.93 | 2.11 | 1.68 | 1.34 | 1.23 | 1.47 | 1.68 | 1.79 | 1.43 | 1.28 |
Month 12 | ||||||||||
PASDAS | 2.51 | 3.05 | 2.07 | – | – | 2.10 | 2.21 | 1.60 | – | – |
DAPSA | 1.50 | 1.57 | 1.30 | – | – | 1.60 | 1.41 | 1.36 | – | – |
CPDAI | 1.95 | 2.12 | 1.59 | – | – | 1.59 | 1.64 | 1.33 | – | – |
DAS28–3(CRP) | 2.25 | 2.18 | 1.77 | – | – | 1.69 | 1.65 | 1.71 | – | – |